At present, the company has built a 4,500-square-meter workshop in the Biomedical Park of Wuhan Donghu High-tech Development Zone, and is undergoing GMP transformation. The design and production capacity of the plant is 6.5438 million boxes of polypeptide oral liquid products every year, and it will also produce polypeptide raw materials, polypeptide drinks, polypeptide tablets and capsules, and polypeptide cosmetics, with an annual production capacity of 2 billion yuan. The company also invested and registered Wuhan Enzyme Polypeptide Biotechnology Co., Ltd. in Wuhan Donghu High-tech Development Zone; Hubei Pueraria Peptide Beverage Biotechnology Co., Ltd. was established in Macheng, an old revolutionary area in Hubei, with a daily output of10.2 million bottles. Recently, the company has completed the counseling for the listing of the New Third Board, and plans to officially list the New Third Board before the end of 20 13.
The company's business objectives are: to enlarge and strengthen the enzymatic polypeptide industry, take peptides as the new basic nutrition for all mankind, strengthen China people with peptides, and make China people become "Oriental strongmen" in the field of human health! .